IP Library Granted Patent US 6,900,218
Granted Patent B2
US 6,900,218 · App. 10/138,938 · Granted May 31, 2005

Pyruvate derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,900,218
App. No.
10/138,938
Granted
May 31, 2005
Kind
B2
Abstract

Certain known and novel pyruvate derivatives are particularly active in restoring or preserving metabolic integrity in oxidatively competent cells that have been subjected to oxygen deprivation. These pyruvate-derived compounds include, but are not limited to oximes, amides, pyruvate analogues, modified pyruvate analogues, esters of pyruvate (e.g., polyol-pyruvate esters, pyruvate thioesters, glycerol-pyruvate esters and dihydroxyacetone-pyruvate esters). Such pyruvate derivatives (including single tautomers, single stereoisomers and mixtures of tautomers and/or stereoisomers, and the pharmaceutically acceptable salts thereof) are useful in the manufacture of pharmaceutical compositions for treating a number of conditions characterized by oxidative stress.

Claims (16)

1. The compound selected from:

3-(5-chloro-benzothiazol-2-ylsulfanyl)-2-hydroxyimino-propionic acid ethyl ester,

2-hydroxyimino-3-(5-methoxy-1H-benzoimidazol-2-ylsulfanyl)-propionic acid ethyl ester, and

3-(1H-benzoimidazol-2-ylsulfanyl)-2-hydroxyimino-propionic acid ethyl ester,

or a single tautomer, single stereoisomer, a mixture of tautomers and/or stereoisomers, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical formulation comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

3. The compound selected from:

3-(1H-benzoimidazol-2-ylsulfanyl)-2-oxo-propionic acid,

2-oxo-3-(4-oxo-3,4-dihydro-quinazolin-2-ylsulfanyl)-propionic acid ethyl ester,

3-(benzoselenazol-2-ylsulfanyl)-2-oxo-propionic acid ethyl ester,

3-(1H-benzoimidazol-2-ylsulfanyl)-2-oxo-propionic acid ethyl ester,

3-(5-chloro-benzothiazol-2-ylsulfanyl)-2-oxo-propionic acid ethyl ester,

3-(5-methoxy-benzoimidazol-2-ylsulfanyl)-2-oxo-propionic acid ethyl ester, and

3-(4,5-dihydro-thiazol-2-ylsulfanyl)-2-oxo-propionic acid ethyl ester,

or a single tautomer, single stercoisomer, a mixture of tautomers and/or stereoisomers, or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical formulation comprising a compound of claim 3 and a pharmaceutically acceptable excipient.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2007
From: GAILLEO PHARMACEUTICALS, INC.
To: MONSANTO TECHNOLOGY, LLC.
Reel/Frame 018816/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2007
From: GALILEO PHARMACEUTICALS, INC.
To: MONSANTO TECHNOLOGY, LLC.
Reel/Frame 018855/0824 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2006
From: ALLOY VENTURES, INC. AS SECURED PARTY AND AS COLLATERAL AGENT FOR ADDITIONAL SECURED PARTIES UNDER THE SECURED NOTE PURCHASE AGREEMENT DATED AS OF DECEMBER 22, 2005
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 018563/0590 →
SECURITY AGREEMENT Recorded Dec 22, 2005
From: GALILEO PHARMACEUTICALS, INC.
To: ALLOY VENTURES, INC.
Reel/Frame 016937/0001 →